G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because, once again, that familiar routine of meetings, deadlines, and the like has returned. You knew this would happen, though, yes? To cope, of course, we are quaffing cups of stimulation — we are indulging our taste for Southern Pecan, for those keeping track — and invite you to join us. Meanwhile, here are some tidbits. Hope you have a smashing day and do keep in touch. We appreciate your ideas, thoughts, and tips …

Drug makers spent $5.6 billion on direct-to-consumer ads last year, a 9 percent increase, according to Medical Marketing & Media, citing data from Nielsen. And once again, Pfizer and Bristol-Myers Squibb took the two top spots among drug makers, spending $1.1 billion and $458 million, respectively. AbbVie, Eli Lilly, and Allergan rounded out the top five spenders. Bristol-Myers Squibb spent more than $170 million on the Opdivo cancer drug alone.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy